<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Creative Medical Technology Holdings Inc — News on 6ix</title>
    <link>https://6ix.com/company/creative-medical-technology-holdings-inc</link>
    <description>Latest news and press releases for Creative Medical Technology Holdings Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 28 Apr 2026 13:01:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/creative-medical-technology-holdings-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683553f278dffbe2df0e8af1.webp</url>
      <title>Creative Medical Technology Holdings Inc</title>
      <link>https://6ix.com/company/creative-medical-technology-holdings-inc</link>
    </image>
    <item>
      <title>Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies</title>
      <link>https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-inc-reports-breakthrough-93percent-response-rate-in-ultrasometm-knee-osteoarthritis-program-expanding-celz-201-platform-into-scalable-cell-free-regenerative-therapies</link>
      <guid isPermaLink="true">https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-inc-reports-breakthrough-93percent-response-rate-in-ultrasometm-knee-osteoarthritis-program-expanding-celz-201-platform-into-scalable-cell-free-regenerative-therapies</guid>
      <pubDate>Tue, 28 Apr 2026 13:01:00 GMT</pubDate>
      <description>Ultrasome™ Demonstrates Strong Clinical Signal While Leveraging GMP-Produced CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis Market PHOENIX, April 28, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced breakthrough positive results from its pilot study of Ultrasome™, the Company’s proprietary cell-free regenerative therapy for the treatment of osteo</description>
    </item>
    <item>
      <title>Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline</title>
      <link>https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-achieves-140000844</link>
      <guid isPermaLink="true">https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-achieves-140000844</guid>
      <pubDate>Tue, 10 Feb 2026 14:00:00 GMT</pubDate>
      <description>WHO recognition of “etaroleucel” (CELZ-101) builds on prior “olastrocel” (CELZ-201) milestone, reinforcing platform credibility and supporting multi-program executionPHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) m</description>
    </item>
    <item>
      <title>Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain</title>
      <link>https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-reaches-141500146</link>
      <guid isPermaLink="true">https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-reaches-141500146</guid>
      <pubDate>Tue, 13 Jan 2026 14:15:00 GMT</pubDate>
      <description>Data Show Strong Functional and Pain Improvements Supported by Excellent Safety ProfilePHOENIX, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced positive interim 180-day follow-up data from its FDA-cleared ADAPT clinical trial evaluating CELZ-201 (Olastrocel), the Company’s proprietary perinatal tissue-derived cell the</description>
    </item>
    <item>
      <title>Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative</title>
      <link>https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-receives-141500866</link>
      <guid isPermaLink="true">https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-receives-141500866</guid>
      <pubDate>Tue, 06 Jan 2026 14:15:00 GMT</pubDate>
      <description>PHOENIX, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company advancing regenerative medicine and AI-enabled biodefense solutions, today announced that its BioDefense Inc. Burn Pit Initiative has received regulatory approval to proceed, marking a significant milestone in the Company’s mission to address the long-term health consequences of toxic burn pit exposure among U.S. milita</description>
    </item>
    <item>
      <title>Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point</title>
      <link>https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-inc-141500132</link>
      <guid isPermaLink="true">https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-inc-141500132</guid>
      <pubDate>Wed, 17 Dec 2025 14:15:00 GMT</pubDate>
      <description>Completion of Enrollment Positions CELZ for Near-Term Data Catalysts and Accelerates Path Toward Commercialization of a Transformative, Non-Opioid Therapy for Chronic Lower Back PainPHOENIX, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced the successful completion of patient enrollment in its FDA-cleared ADAPT clinical trial evaluating CELZ-201 (Olastroce</description>
    </item>
    <item>
      <title>Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201</title>
      <link>https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-announces-141500298</link>
      <guid isPermaLink="true">https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-announces-141500298</guid>
      <pubDate>Tue, 02 Dec 2025 14:15:00 GMT</pubDate>
      <description>Global assignment of this unique name enhances international clarity, strengthens regulatory positioning, and supports olastrocel’s advancement across large unmet-need global marketsPHOENIX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company developing next-generation regenerative and immune cell therapies, today announced that the World Health Organization (WHO) has approved “o</description>
    </item>
    <item>
      <title>Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits</title>
      <link>https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-inc-131500272</link>
      <guid isPermaLink="true">https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-inc-131500272</guid>
      <pubDate>Thu, 30 Oct 2025 13:15:00 GMT</pubDate>
      <description>Selects Greenstone Biosciences to Accelerate AI-Driven iPSC Precision Medicine PlatformPHOENIX, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage leader in regenerative and cellular innovation, today announced the official launch of its BioDefense Inc. Veterans Initiative, believed to be a first-of-its-kind national program to combat the devastating long-term effects of toxic burn pit exposure among</description>
    </item>
    <item>
      <title>Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds</title>
      <link>https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-announces-130000041</link>
      <guid isPermaLink="true">https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-announces-130000041</guid>
      <pubDate>Wed, 29 Oct 2025 13:00:00 GMT</pubDate>
      <description>PHOENIX, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (Nasdaq: CELZ) (the “Company”), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today announced that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to an aggregate of 1,116,136 shares of common stock of the Company originally issued in March 2025, at their current exercise price of $3.7</description>
    </item>
    <item>
      <title>Creative Medical Technology Holdings Issues Letter to Shareholders</title>
      <link>https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-issues-121500357</link>
      <guid isPermaLink="true">https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-issues-121500357</guid>
      <pubDate>Mon, 27 Oct 2025 12:15:00 GMT</pubDate>
      <description>Ongoing Phase II Clinical Trials, Recently Issued Patents, and AI Integration Initiatives Set the Stage for Continuing Progress in 2026PHOENIX, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today issued a Letter to Shareholders from Timothy Warbington, Co-Founder and Chief Executive Officer. Dear Fellow Shareholders: 2025 has been a la</description>
    </item>
    <item>
      <title>Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs</title>
      <link>https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-congratulates-131500264</link>
      <guid isPermaLink="true">https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-congratulates-131500264</guid>
      <pubDate>Tue, 07 Oct 2025 13:15:00 GMT</pubDate>
      <description>Recent Issuance of U.S. Patents Covering ImmCelz™ — Supercharged Regulatory T Cell Programs in Heart Failure and Type 1 Diabetes Reinforce Creative Medical’s Similar Research FocusPHOENIX, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today congratulated Mary E. Brunkow, Ph.D., Fred Ramsdell, Ph.D., and Shimon Sakaguchi, M.D., Ph.D. on</description>
    </item>
    <item>
      <title>Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain</title>
      <link>https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-secures-130100093</link>
      <guid isPermaLink="true">https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-secures-130100093</guid>
      <pubDate>Wed, 13 Aug 2025 13:01:00 GMT</pubDate>
      <description>PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on regenerative and immune cellular therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead investigational therapy, CELZ-201-DDT, for the treatment of degenerative disc disease (DDD), a major cause of chronic lower back pain and disability. This designation positions CELZ-201-DDT am</description>
    </item>
    <item>
      <title>Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells</title>
      <link>https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-receives-131500694</link>
      <guid isPermaLink="true">https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-receives-131500694</guid>
      <pubDate>Thu, 17 Jul 2025 13:15:00 GMT</pubDate>
      <description>PHOENIX, July 17, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application titled, “Prevention and/or Treatment of Type 1 Diabetes by Augmentation of Myeloid Suppressor Cell Activity.” Once granted, the patent</description>
    </item>
    <item>
      <title>Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling</title>
      <link>https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-receives-120100981</link>
      <guid isPermaLink="true">https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-receives-120100981</guid>
      <pubDate>Fri, 11 Jul 2025 12:01:00 GMT</pubDate>
      <description>PHOENIX, July 11, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application titled, “Treatment Of Heart Failure And/Or Post Infarct Pathological Remodeling By Ex Vivo Reprogrammed Immune Cells.” Once granted, t</description>
    </item>
    <item>
      <title>Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain</title>
      <link>https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-secures-115000650</link>
      <guid isPermaLink="true">https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-secures-115000650</guid>
      <pubDate>Thu, 20 Mar 2025 11:50:00 GMT</pubDate>
      <description>Positive Interim Blinded Data Supports Advancement Toward Potential Pivotal Phase 3 StudyPHOENIX, March 20, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (the “Company”), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded dose escalation for its ongoing Phase 1/2 trial of StemSpine® using AlloStem™ (CELZ-201-DDT), the Company’s proprietary allog</description>
    </item>
    <item>
      <title>Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds</title>
      <link>https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-announces-131000080</link>
      <guid isPermaLink="true">https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-announces-131000080</guid>
      <pubDate>Thu, 06 Mar 2025 13:10:00 GMT</pubDate>
      <description>PHOENIX, March 06, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (Nasdaq: CELZ) (the “Company”), a leading biotechnology innovator in regenerative medicine, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 837,104 shares of common stock of the Company originally issued in October 2024 at their current exercise price of $4.42 per share. Th</description>
    </item>
    <item>
      <title>Creative Medical Technology Holdings Applauds Presidential Initiative to Expand IVF Access, Showcasing OvaStem® Program&apos;s Success and Growth Potential</title>
      <link>https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-applauds-130000205</link>
      <guid isPermaLink="true">https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-applauds-130000205</guid>
      <pubDate>Thu, 20 Feb 2025 13:00:00 GMT</pubDate>
      <description>OvaStem® Demonstrates Strong Long-Term Efficacy with No Safety Concerns, Backed by Pending Orphan Drug Designation for AlloStem®PHOENIX, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a leading biotechnology innovator in regenerative medicine, enthusiastically supports President Donald J. Trump’s executive order expanding access to in vitro fertilization (IVF). This initiative directly aligns with the company’s vision to transform reproductive health</description>
    </item>
    <item>
      <title>Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™</title>
      <link>https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-announces-mid-term-follow-up-study-data-reporting-significant-reduction-in-opioid-use-by-chronic-lower-back-pain-patients-undergoing-stemspiner-procedure-using-allostemtm</link>
      <guid isPermaLink="true">https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-announces-mid-term-follow-up-study-data-reporting-significant-reduction-in-opioid-use-by-chronic-lower-back-pain-patients-undergoing-stemspiner-procedure-using-allostemtm</guid>
      <pubDate>Fri, 14 Feb 2025 05:00:00 GMT</pubDate>
      <description>Study Demonstrates Robust Efficacy and Strong Safety Profile PHOENIX, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (&quot;Creative</description>
    </item>
    <item>
      <title>Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program</title>
      <link>https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-reports-positive-one-year-results-for-allostemtm-type-2-diabetes-program</link>
      <guid isPermaLink="true">https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-reports-positive-one-year-results-for-allostemtm-type-2-diabetes-program</guid>
      <pubDate>Tue, 11 Feb 2025 05:00:00 GMT</pubDate>
      <description>Significant Efficacy and No Serious Adverse Effects Observed with CELZ-201 PHOENIX, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings,</description>
    </item>
    <item>
      <title>Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development</title>
      <link>https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-expands-collaboration-with-greenstone-biosciences-to-accelerate-ipscelz-pipeline-development</link>
      <guid isPermaLink="true">https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-expands-collaboration-with-greenstone-biosciences-to-accelerate-ipscelz-pipeline-development</guid>
      <pubDate>Wed, 05 Feb 2025 05:00:00 GMT</pubDate>
      <description>PHOENIX, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical”), a clinical-stage biotechnology</description>
    </item>
    <item>
      <title>Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain</title>
      <link>https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-announces-positive-initial-safety-tolerability-and-efficacy-data-from-first-cohort-in-phase-12-trial-of-celz-201-ddt-for-chronic-back-pain</link>
      <guid isPermaLink="true">https://6ix.com/company/creative-medical-technology-holdings-inc/news/creative-medical-technology-holdings-announces-positive-initial-safety-tolerability-and-efficacy-data-from-first-cohort-in-phase-12-trial-of-celz-201-ddt-for-chronic-back-pain</guid>
      <pubDate>Thu, 30 Jan 2025 05:00:00 GMT</pubDate>
      <description>PHOENIX, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on</description>
    </item>
  </channel>
</rss>